Abstract
We report a reactivation of hepatitis B virus (HBV) in an human immunodeficiency virus (HIV) patient despite a serological profile of past HBV infection with anti-HBs and anti-HBc antibodies, following the interruption of tenofovir/emtricitabine. In HBV-HIV co-infected patients, close monitoring of HBV viral load and serological markers is required for antiretroviral management, particularly after interruption of drugs active for HBV.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
